- Home
- HHS vs RLYB Comparison
HHS vs RLYB Comparison
Compare HHS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | RLYB |
|---|---|---|
| Founded | 1923 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 24.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HHS | RLYB |
|---|---|---|
| Price | $3.34 | $0.73 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.0K | ★ 176.7K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,841,000.00 | $674,000.00 |
| Revenue This Year | $6.54 | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $2.33 | $0.22 |
| 52 Week High | $5.59 | $1.08 |
Technical Indicators
Market Signals| Indicator | HHS | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 54.03 |
| Support Level | $3.04 | $0.71 |
| Resistance Level | $3.35 | $0.80 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 75.38 | 59.76 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.